A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer. Gaillard S, Verma N, Berg M, Harrison J, et al. Gynecol Oncol 2025;194:41-47.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Gaillard S, Verma N, Berg M, Harrison J, et al. A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer. Gynecol Oncol 2025;194:41-47.
PMID: 39951918